Literature DB >> 16625618

Oral antibiotics versus parenteral antibiotics for severe pneumonia in children.

M X Rojas1, C Granados.   

Abstract

BACKGROUND: Acute respiratory infection (ARI) is one of the leading causes of morbidity and mortality in children under five years of age in developing countries. When hospitalisation is required, the usual practice includes administering parenteral antibiotics if a bacterial infection is suspected. This has disadvantages as it causes pain and discomfort to the children, which may lead to treatment refusal or reduced compliance. It is also associated with needle-related complications. In some settings this equipment is in short supply or unavailable necessitating transfer of the child, which increases risks and healthcare costs.
OBJECTIVES: To determine the equivalence in effectiveness and safety of oral antibiotic compared to parenteral antibiotic therapies in the treatment of severe pneumonia in children between three months and five years of age. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2005); MEDLINE (January 1966 to July 2005); EMBASE (January 1990 to July 2005) and LILACS (February 2005). SELECTION CRITERIA: The review included published or unpublished randomised controlled trials (RCTs) and quasi-RCTs comparing any oral antibiotic therapy with any parenteral antibiotic therapy for the treatment of severe pneumonia in children from three months to five years of age. DATA COLLECTION AND ANALYSIS: The search yielded more than 1300 titles. Only three studies met all criteria for eligibility. One of the identified trials is yet to publish its results. We did not perform a meta-analysis because of clinical heterogeneity of therapies compared in the included trials. MAIN
RESULTS: Campbell 1988 compared oral co-trimoxazole versus intramuscular procaine penicillin followed by oral ampicillin in 134 children. At the seventh day of follow up, treatment failure occurred in 6/66 (9.1%) in the oral co-trimoxazole group and 7/68 (10.2%) in the combined-treatment group. The risk difference was -0.01% (95% confidence interval (CI) -0.11 to 0.09). The APPIS Group 2004 evaluated 1702 patients comparing oral amoxicillin versus intravenous penicillin for two days followed by oral amoxicillin. After 48 hours, treatment failure occurred in 161/845 (19%) in the amoxicillin group and 167/857 (19%) in the parenteral penicillin group. The risk difference was -0.4% (95% CI -4.2 to 3.3). The authors reported similar recovery in both groups at 5 and 14 days. AUTHORS'
CONCLUSIONS: Oral therapy appears to be an effective and safe alternative to parenteral antibiotics in hospitalised children with severe pneumonia who do not have any serious signs or symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16625618      PMCID: PMC6885030          DOI: 10.1002/14651858.CD004979.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  40 in total

1.  Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial.

Authors:  A Castro-Guardiola; A L Viejo-Rodríguez; S Soler-Simon; A Armengou-Arxé; V Bisbe-Company; G Peñarroja-Matutano; J Bisbe-Company; F García-Bragado
Journal:  Am J Med       Date:  2001-10-01       Impact factor: 4.965

2.  The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries.

Authors:  M Garenne; C Ronsmans; H Campbell
Journal:  World Health Stat Q       Date:  1992

3.  Trial of co-trimoxazole versus procaine penicillin with ampicillin in treatment of community-acquired pneumonia in young Gambian children.

Authors:  H Campbell; P Byass; I M Forgie; K P O'Neill; N Lloyd-Evans; B M Greenwood
Journal:  Lancet       Date:  1988-11-19       Impact factor: 79.321

4.  Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay.

Authors:  N J Ehrenkranz; D E Nerenberg; J M Shultz; K C Slater
Journal:  Infect Control Hosp Epidemiol       Date:  1992-01       Impact factor: 3.254

5.  Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial.

Authors: 
Journal:  Lancet       Date:  2002-09-14       Impact factor: 79.321

6.  [Clinical efficacy of oral clarithromycin monotherapy in patients with mild or moderate community-acquired pneumonia].

Authors:  Rei Fujiki; Toru Rikimaru; Hisamichi Aizawa; Tomotaka Kawayama
Journal:  Jpn J Antibiot       Date:  2003-12

7.  Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study.

Authors:  Emmanuel Addo-Yobo; Noel Chisaka; Mumtaz Hassan; Patricia Hibberd; Juan M Lozano; Prakash Jeena; William B MacLeod; Irene Maulen; Archana Patel; Shamim Qazi; Donald M Thea; Ngoc Tuong Vy Nguyen
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  [Use of oral antibacterial drugs in the treatment of acute pneumonia in children].

Authors:  A M Fedorov; V K Tatochenko; B E Khaĭrulin
Journal:  Pediatriia       Date:  1992

9.  Cefetamet pivoxil in paediatric patients suffering from lower respiratory tract infections.

Authors:  M Gatzola-Karaveli; N Vogiatzis; I Rousso; S Sklavuno-Tsurutsoglu; G Germano; M Kissling
Journal:  Pharmatherapeutica       Date:  1989

10.  Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study.

Authors:  B Friis; P Andersen; E Brenøe; A Hornsleth; A Jensen; F U Knudsen; P A Krasilnikoff; C H Mordhorst; S Nielsen; P Uldall
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

View more
  13 in total

1.  Does Bradford's Law of Scattering predict the size of the literature in Cochrane Reviews?

Authors:  Charlotte E Nash-Stewart; Lisa M Kruesi; Chris B Del Mar
Journal:  J Med Libr Assoc       Date:  2012-04

2.  Are parents of children hospitalized with severe community-acquired pneumonia more satisfied with care when physicians allow them to share decisions on the antibiotic route?

Authors:  Paola Rosati; Viviana Di Salvo; Stefania Crudo; Roberto D'Amico; Cecilia Carlino; Maria Rosaria Marchili; Michaela Gonfiantini; Vincenzo Di Ciommo
Journal:  Health Expect       Date:  2014-04-28       Impact factor: 3.377

Review 3.  Antibiotics for community-acquired pneumonia in children.

Authors:  Rakesh Lodha; Sushil K Kabra; Ravindra M Pandey
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

Review 4.  Management of community-acquired pneumonia in children.

Authors:  Krishne Chetty; Anne H Thomson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 5.  Interventions for cellulitis and erysipelas.

Authors:  Sally A Kilburn; Peter Featherstone; Bernie Higgins; Richard Brindle
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

Review 6.  Treatment of severe community-acquired pneumonia with oral amoxicillin in under-five children in developing country: a systematic review.

Authors:  Rashmi Ranjan Das; Meenu Singh
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

7.  Evidence for perinatal and child health care guidelines in crisis settings: can Cochrane help?

Authors:  Tari J Turner; Hayley Barnes; Jane Reid; Marie Garrubba
Journal:  BMC Public Health       Date:  2010-03-29       Impact factor: 3.295

Review 8.  Experience developing national evidence-based clinical guidelines for childhood pneumonia in a low-income setting--making the GRADE?

Authors:  Ambrose Agweyu; Newton Opiyo; Mike English
Journal:  BMC Pediatr       Date:  2012-01-01       Impact factor: 2.125

Review 9.  Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia.

Authors:  Rashmi R Das; Meenu Singh; Sushree S Naik
Journal:  Cochrane Database Syst Rev       Date:  2018-07-19

10.  Efficacy of high doses of oral penicillin versus amoxicillin in the treatment of adults with non-severe pneumonia attended in the community: study protocol for a randomised controlled trial.

Authors:  Carl Llor; Javier Arranz; Rosa Morros; Anna García-Sangenís; Helena Pera; Joan Llobera; Mireia Guillén-Solà; Eugenia Carandell; Jesús Ortega; Silvia Hernández; Marc Miravitlles
Journal:  BMC Fam Pract       Date:  2013-04-17       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.